Home
About Us
Products
R & D
Investors
News
- Company News
- Press Release
Join Us
- Recruitment
- Working at RemeGen
Contact Us

Lang

中文简体
中文繁体

Company News

Home > News > Company News >

Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin

09 2021.08

Final Joint Press Release.pdf.pdf

return

About Us

Our Company
Our Vision
Our Board of Directors
Our Management Team
Scientific Advisory Board

Products

Telitacicept
Disitamab Vedotin
Product Pipeline
Production and Manufacturing
Quality Assurance

R & D

Renovation Capabilities
Technology Platform
Talent Team

Investors

Information Disclosure
Corporate Governance
IR Contacts

News

Company News
Press Release

Join Us

Recruitment
Working at RemeGen

Contact Us

Company Address
Clinical Trial
Products Consulting
Human Resource
Adverse drug reaction reports

58 Beijing Middle Road, Yantai Shandong, China.

（+86）0535-3573511

: Company Wechat

ICP：鲁ICP备11031710号-4